obesity

Drugs like Ozempic and Wegovy were originally developed and described as obesity treatments for patients with medical need, but they are increasingly marketed and used as lifestyle drugs for customers seeking cosmetic or wellness benefits. Commentators note this reframing raises questions about access for people with genuine medical need, pricing, and how the pharmaceutical industry positions these medicines.

Stroke rates among younger adults have nearly doubled, according to a report highlighted by University of Cincinnati researchers. The increase in adults under around 55 marks a shift from stroke's traditional reputation as an older person's illness, and is drawing attention to rising rates of obesity, high blood pressure and diabetes as likely contributing factors. Health experts are urging younger people to monitor blood pressure and adopt healthier lifestyles to reduce their risk.

GLP-1 medications such as Ozempic and Wegovy are being discussed as a new approach to weight loss, moving beyond diet and exercise as the standard advice. Johns Hopkins University is among the institutions weighing in on how these drugs work and what their rise means for obesity treatment. The conversation centers on effectiveness, costs, and how widely these drugs will change care.

India has proposed banning the sale of junk food in school canteens and within 50 meters of schools, in an effort to curb rising obesity and diabetes rates among children. The measure tightens existing school food rules as health officials grow concerned over children's diets, and it is drawing attention to how governments regulate food sales near educational institutions.

An obesity medicine doctor is addressing the growing trend of microdosing Ozempic, the diabetes drug widely used for weight loss, explaining the safety concerns and potential risks of taking lower-than-standard doses. The doctor notes there are limited situations where a low dose may be appropriate, but warns patients against adjusting medication on their own without medical supervision.

New research suggests the weight-loss drugs Zepbound and Mounjaro may activate brown fat, a type of body tissue that burns calories to generate heat. If confirmed, the findings could help explain part of how the medications drive weight loss beyond appetite suppression, and point to new ways of boosting metabolism in obesity treatment.

Health experts say weight loss drugs such as GLP-1 medications could offer benefits beyond slimming, potentially helping treat women's reproductive health issues. The suggestion points to a possible new use for a class of medicines already in high demand, and it is drawing attention to how obesity-related treatments might intersect with conditions like polycystic ovary syndrome and fertility problems.

A new study has connected the use of GLP-1 weight-loss and diabetes medications in children with nutritional deficiencies, according to Scripps News, which published an interactive report on the findings. The drugs, widely prescribed to minors amid rising childhood obesity rates, may leave young users short of key nutrients. The findings add to ongoing debate over the safety and supervision of GLP-1 treatment in pediatric patients.

New research suggests that weight regained after dieting may be driven by brain biology rather than simply a lack of willpower, pointing to neural mechanisms that push the body back toward its previous weight after a diet ends. The findings are being discussed as a possible shift in how obesity and dieting failure are understood, with implications for treatment and public attitudes toward weight loss.

Eli Lilly has announced the Lilly Change the Course Commitment, a new initiative aimed at narrowing treatment gaps in diabetes and obesity care in low- and middle-income countries. The pharmaceutical company says the programme will focus on expanding access to treatment where need is greatest. Details on funding and specific country plans have not yet been widely reported.

A new study suggests that removing ultra-processed food from school menus will be a difficult task. The finding highlights practical obstacles schools face in offering fresher, less processed meals to pupils. The research is drawing attention amid growing public and political concern over ultra-processed food in children's diets and its links to obesity and poor health outcomes.

Major food companies in India are urging regulators to reconsider the red colour proposed for warning labels on packaged foods, Reuters reports. The industry argues the red symbol could stigmatise products, while health advocates support strong front-of-pack warnings to combat rising obesity, diabetes and high salt, sugar and fat consumption in the country.

Efforts to ban ultra-processed foods from public schools are running into significant practical obstacles, according to reporting highlighted by News-Medical. Schools face challenges around sourcing affordable alternatives, reworking contracts with food suppliers, and meeting nutrition standards on tight budgets. The debate touches on children's health, obesity prevention, and the feasibility of overhauling cafeteria menus at scale.

New research suggests tirzepatide, the weight-loss and diabetes drug sold as Mounjaro and Zepbound, may activate brown fat, a type of tissue that burns calories to generate heat. If confirmed, the finding could help explain the drug's effectiveness and open new avenues in obesity treatment. Coverage is so far limited, with fitness outlets picking up the claim and experts urging caution until results are published in full.

The Atlantic reports that GLP-1 medications such as Ozempic and Wegovy are changing how scientists and the public understand the links between obesity, appetite and mental health. Beyond weight loss, emerging discussion suggests these drugs may influence mood, cravings and compulsive behaviours, prompting debate among researchers and clinicians about their wider psychological effects.

Fitness YouTuber MattDoesFitness has published a documentary-style video about spending 48 hours in what he describes as the UK's fattest town, exploring residents' diets, lifestyles and local attitudes to weight and health. The video has drawn large engagement, with hundreds of thousands of likes, and viewers are debating whether the piece sheds light on Britain's obesity crisis or sensationalises it.

Fitness YouTuber MattDoesFitness has released an investigation into the town with the highest obesity levels in the UK, exploring local eating habits, health services and residents' perspectives on weight. The video has drawn strong engagement, with viewers debating whether the issue reflects personal choices, poverty and food environment, or broader public health policy failures in Britain.

Ultra-processed foods are industrial products made with ingredients rarely found in home kitchens, such as additives, flavourings, emulsifiers and preservatives, and include items like soft drinks, packaged snacks and ready meals. The explainer comes amid growing scientific and public debate about links between diets high in such foods and health problems including obesity, heart disease and diabetes.

A new obesity drug has been described as the most powerful yet after trial participants reportedly lost up to 25% of their body weight. The results, reported by Ars Technica, would surpass figures associated with current GLP-1 medications such as Wegovy and Zepbound, intensifying competition among drugmakers in the fast-growing weight-loss treatment market.

ICBA Africa is advocating for evidence-based dialogue on low- and no-calorie sweeteners across the African continent, according to a piece published in African Business. The organisation's effort comes amid ongoing debate over the health effects of sugar substitutes and their role in addressing rising rates of obesity and diabetes in Africa.